Significance of Soluble CD200 in plasma and serum of human breast cancer patients
Abstract
The composition of the tumour microenvironment is important for regulation of metastasis in breast cancer, and targeting immune inhibitory receptors has recently become a focus for activating anti-tumour immune responses in the host. In the EMT6 mouse breast cancer model, expression of the immunoregulatory molecule CD200 on the surface of a subpopulation of cancer cells results in a suppression of anti-tumour immunity and increased metastasis to local draining lymph nodes (DLN). CD200 can also be released by host or tumour cells into the circulation in a soluble form.
In this study, we investigated the levels of sCD200 in human breast cancer patient plasma using an ELISA. We correlated our findings with clinical characteristics of breast cancer and with cell surface CD200 expression by the cells in the breast tumor, as detected by qPCR and immunostaining. Our data support the hypothesis that CD200 may be important in the progression of breast cancer.
Keywords
Full Text:
Subscribers OnlyReferences
Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
El Saghir NS, Tfayli A, Hatoum HA, et al. Treatment of metastatic breast cancer: state-of-the-art, subtypes and perspectives. Crit Rev Oncol Hematol 2011;80:433-49.
Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
Husemann Y, Geigl JB, Schubert F, et al. Systemic spread is an early step in breast cancer. Cancer Cell 2008;13:58-68.
Engel J, Eckel R, Kerr J, et al. The process of metastasisation for breast cancer. European Journal of Cancer 2003;39:1794-1806.
Klein CA. The systemic progression of human cancer: a focus on the individual disseminated cancer cell--the unit of selection. Adv Cancer Res 2003;89:35-67.
Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-77.
Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006;108:4194-7.
Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia. Volume 21. England, 2007:566-8.
Siva A, Xin H, Qin F, et al. Immune modulation by melanoma and ovarian tumor cells through expression of CD200. Cancer Immunol Immunother 2008;57:987-96.
Gorczynski RM, Clark DA, Erin N, et al. Role of CD200 expression in regulation of metastasis of EMT6 tumor cells in mice. Breast Cancer Res Treat 2011;130:49-60.
Podnos A, Clark DA, Erin N, et al. Further evidence for a role of tumor CD200 expression in breast cancer metastasis: decreased metastasis in CD200R1KO mice or using CD200-silenced EMT6. Breast Cancer Res Treat 2012;136:117-27.
Gorczynski RM, Chen Z, Khatri I, et al. Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling. Breast Cancer Res Treat 2013;142:271-82.
Wong KK, Brenneman F, Chesney A, et al. Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. Cancer Res 2012;72:4931-43.
Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM et al CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy J for Immunotherapy of Cancer 2014; DOI: 10.1186/s40425-014-0046-9
Chen DX, Gorczynski RM. Discrete monoclonal antibodies define functionally important epitopes in the. Transplantation 2005;79:282-8.
Wong KK, Khatri I, Shaha S, et al. The role of CD200 in immunity to B cell lymphoma. J Leukoc Biol 2010;88:361-72.
Kretz-Rommel A, Bowdish KS. Rationale for anti-CD200 immunotherapy in B-CLL and other hematologic malignancies: new concepts in blocking immune suppression. Expert Opin Biol Ther 2008;8:5-15.
Celik B, Yalcin AD, Gizem EG, et al. Proteomics pattern of peritoneal sApo-2L but not CD200 (OX-2) as a possible screening biomarker for stage 4 metastatic ovarian, endometrial, ad breast carcinoma. Journal of Balkan Union of Oncology: Antalya Training Hospital, 2015.
21. Bisgnin A, Yalcin AD, Gumuslu S, et al. Correlation of serum proteomics patterns of sCD200 (OX-2), sApo-2L (sTRAIL), vitamin-D and homocysteine to quantitative FDG-PET/CT findings in newly diagnosed non-small cell lung cancer. J BUON 2013;18:1099-100.
Kos O, Hughson RL, Hart DA, et al. Elevated serum soluble CD200 and CD200R as surrogate markers of bone loss under bed rest conditions. Bone 2014;60:33-40
Akman-Karakas A, Yalcin AD, Koc S, et al. Serum soluble CD200 level was higher in patients with bullous pemphigoid during the active phase of the disease than for healthy individuals. Clin Lab 2014;60:1237-40
Erin N, Podnos A, Tanriover G, Duymus O, Cote E, Khatri I, Gorczynski RM. Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response. Oncogene 2014.; 34: 3860-3870
DOI: http://dx.doi.org/10.18103/imr.v2i10.258
Refbacks
- There are currently no refbacks.